Table 3.

Rates of total number of 30-day heart failure re-hospitalizations across level of kidney function among participants with chronic kidney disease

					Model 1	Model 2	Model 3
	Number of participants	Number of HF hospitalizations	Total number of 30-day HF rehospitalizations	Crude rate, per 100 pys (95% CIs)
Overall	3791	1706	238	0.8 (0.6, 1.0)
eGFR stage
eGFR ≥ 45	1714	437	53	0.4 (0.2, 0.5)	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)
eGFR 30-44	1379	766	111	1.1 (0.7, 1.4)	2.5 (1.5, 4.1)	2.2 (1.3, 3.6)	1.9 (1.2, 3.1)
eGFR < 30	698	503	74	1.5 (0.8, 2.2)	3.4 (1.9, 6.2)	3.0 (1.6, 5.6)	2.6 (1.4, 4.7)
Albuminuria
uACR < 30	1629	383	43	0.3 (0.2, 0.4)	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)
uACR 30 - < 300	1001	510	80	1.0 (0.6, 1.5)	3.2 (1.8, 5.5)	2.7 (1.5, 4.7)	2.7 (1.5, 4.8)
uACR ≥ 300	1161	813	115	1.4 (0.9, 1.9)	4.6 (2.7, 7.7)	3.6 (1.8, 7.1)	3.6 (1.8, 7.3)
CKD category
eGFR ≥ 45, uACR < 300	1401	253	29	0.2 (0.1, 0.4)	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)
eGFR < 45, uACR < 300	1229	640	94	1.0 (0.7, 1.4)	3.4 (1.9, 6.1)	3.2 (1.8, 5.7)	2.8 (1.6, 4.9)
eGFR ≥ 45, uACR > 300	313	184	24	1.0 (0.4, 1.6)	4.5 (2.1, 9.7)	3.6 (1.6, 8.2)	3.8 (1.6, 8.7)
eGFR < 45, uACR > 300	848	629	91	1.5 (0.9, 2.2)	5.5 (3.0, 10.2)	4.2 (2.0, 8.8)	3.8 (1.8, 8.1)

All rate ratios with p-value<0.05

eGFR= estimated glomerular filtration rate; uACR= urine albumin-to-creatinine-ratio

Model 1: age, sex, and race/ethnicity

Model 2: model 1 + diabetes, history of cardiovascular disease, use of lipid-lowering medications, smoking, systolic blood pressure, and body mass index

Model 3: model 2 + use of diuretics, angiotensin-converting-enzyme inhibitors/aldosterone receptor blockers, β-blockers